Background There is a dearth of data on the clinical features and outcomes of active tuberculosis (TB) in pregnancy. Studies have shown varied results and the relationship between TB and adverse pregnancy outcomes remains unclear.
Accepted 22 September 2016. Published online 11 November 2016.
Background There is a dearth of data on the clinical features and outcomes of active tuberculosis (TB) in pregnancy. Studies have shown varied results and the relationship between TB and adverse pregnancy outcomes remains unclear.
Objectives We conducted a systematic review and meta-analysis to evaluate pregnancy outcomes associated with TB.
Search strategy Major databases were searched from inception until December 2015 without restrictions using the terms: 'TB', 'pregnancy', 'maternal morbidity', 'mortality' and 'perinatal morbidity', 'mortality'.
Selection criteria We included studies that compared the outcomes of pregnant women with and without active TB.
Data collection and analysis We computed odds ratios for maternal and perinatal complications, and pooled them using a random effects model. We assessed for heterogeneity using chisquared tests and evaluated its magnitude using the I 2 statistic.
We used the Newcastle-Ottawa scale for quality assessment. 
Introduction
Tuberculosis (TB) is one of the world's deadliest communicable diseases. 1 In 2013, an estimated 9 million people developed active TB and 1.5 million died from the disease; 510 000 of these were women.
1 TB is one of the leading causes of death in women of reproductive age (15-45 years); 2 globally it is estimated that as many as 216 500 pregnant women have active TB. 3 Indirect maternal deaths now account for 28% of total maternal deaths; 15-35% of these deaths are due to TB. 2, 4 Although the greatest burden of TB infection is in resource-limited countries, resource-rich countries have seen a resurgence of TB, largely as a result of an increase in migrant populations. 5 The areas which have the highest TB burden, South-east Asia, Western Pacific and African regions, also have the highest maternal mortality rates. 1 Studies of active TB in pregnancy have shown varied results and the relationship between TB and adverse pregnancy outcomes remains unclear. 6 Quantitative data synthesis can overcome this deficiency and imprecision. Previous reviews have indicated that pregnancy outcomes are worse in women with active TB, but none has been conducted in a systematic manner or included meta-analysis. 7 We conducted a systematic review to collate the evidence on maternal and perinatal outcomes of pregnancies associated with active TB.
Method

Study selection
Medline, Embase, Web of Science and Scopus databases were searched using the subject keywords and MeSH terms for 'TB', 'pregnancy', 'maternal morbidity', 'maternal mortality' and 'perinatal morbidity', and 'perinatal mortality'. We also searched all references of review papers and relevant articles. The search was not restricted by language and included all articles from inception till December 2015 (Appendix S1). Additionally, we searched the reference lists of the included studies for eligible papers. Two independent reviewers (S.S., H.K.) identified all relevant abstracts using pre-specified inclusion and exclusion criteria in a two-stage process. In the first stage, we screened the titles and abstracts of all citations for potentially relevant papers. In the second stage, we examined in detail the full texts of the retrieved papers. Any discrepancies were resolved after discussion with a third reviewer (K.K.). Studies were included if they had a cohort of pregnant women with TB and pregnant women without TB as a control group and had pregnancy outcome data included.
Quality assessment of the included studies
The Newcastle-Ottawa scale was used to assess the quality of the included studies, and to evaluate the risk of bias in the selection, comparability of subjects and cohorts, and of the outcome. 8 Two independent reviewers (S.S. and H.K.) allocated stars for adherence to a pre-specified criterion. Studies that scored four stars for selection, two stars for comparability and three stars for ascertainment of the outcome were regarded as having a low risk of bias. Studies with two or three stars for selection, one for comparability and two for outcome ascertainment were considered to have a medium risk of bias. Any study with a score of one star for selection or outcome ascertainment or zero for any of the three domains was deemed to have a high risk of bias.
Data extraction and analysis
Using a piloted data extraction form, information on study design, setting, population characteristics, TB diagnosis and treatment as well as maternal and perinatal outcomes were obtained. Two independent reviewers (S.S., H.K.) extracted data in 2 9 2 tables for comparative dichotomous outcomes.
Standard WHO definitions were used for the following outcomes: maternal mortality, perinatal mortality and preterm birth. 9, 10 Maternal morbidity was defined as any health condition attributed to and/or aggravated by pregnancy and childbirth that had a negative impact on the woman's wellbeing. 11 We accepted the authors' definitions of other fetal complications such as small for gestational age.
We calculated the odds ratios of adverse pregnancy outcomes in women with TB and women without TB for individual studies and pooled them to obtain an overall estimate using a random effects model, as we anticipated heterogeneity between studies. For continuous data, we computed weighted mean difference, which was pooled using a random effects model. We assessed for heterogeneity between studies using the I 2 tests: (I 2 40-60%: may represent moderate heterogeneity, 50-90%: may represent substantial heterogeneity and 75-100%): considerable heterogeneity. A post-hoc sensitivity analysis was performed to evaluate the impact of excluding studies with a high risk of bias from the analysis. All analyses were undertaken using STATA SE.12 statistical software. 12 
Results
Characteristics of included studies
Thirteen of 7521 studies met the inclusion criteria (Figure 1) . These studies included 3384 pregnant women with active TB and 119 448 healthy pregnant women as controls. The diagnosis of active TB was made by a combination of clinical and radiological findings supported by microbiological and/or histological confirmation. Of the 3384 women with active TB, 2423 (72%) had pulmonary disease, 199 (5.8%) had extra-pulmonary disease and three patients had both pulmonary and extra-pulmonary disease. The site of TB disease was not stated in 22% of cases. 13 Only seven women had HIV co-infection. One study excluded patients with HIV. 13 Not all studies included complete data on timing of diagnosis; of 3384 women with TB, timing of diagnosis was included for 1135 women. The timing of diagnosis and treatment varied among this group; 827 (73%) patients were found to have active TB prior to conception, 127 (11%) in the 1st trimester, 135 (12%) in 2nd trimester and 46 (4%) in the third trimester or the postpartum period. Regimens of anti-tuberculous therapy (ATT) were documented in 62% of studies, the details of which are provided in Table S1 . Furthermore, in five studies the precise proportion of patients who received treatment and the regimen received was not recorded. [14] [15] [16] [17] [18] Nearly half of the studies (6/13) were from low-income and middle-income countries. Sixty-one per cent (8/13) of the studies were published after the year 2000. Ten studies reported on preterm birth as an outcome, six studies reported on low birthweight, seven on perinatal death, four on congenital anomalies, three on asphyxia and two on small for gestational age and acute fetal distress. Low Apgar score at 1 minute was reported by only one study. For maternal outcomes, five studies reported maternal death as an outcome, five described maternal morbidity, five reported on delivery by caesarean section and three reported on the presence of anaemia. Miscarriage and antenatal admission were reported by one study each. Study characteristics are shown in Table S1 .
Quality assessment
The quality of the studies is shown in Figure 2 . All of the included studies had low or medium risk of bias for study selection, and outcome assessment, and 7/13 had low risk of bias for comparability of cohorts. Overall, 7/13 of studies had low or medium risk of bias.
Maternal and perinatal outcomes
Maternal and perinatal outcomes were consistently poorer in pregnant women with active TB infection than in those without. Although not significant, a trend towards more maternal deaths in women with active TB was present (OR 4.1, 95% CI 0.65-25.2; I 2 = 0%). Of the women who died, 50% had HIV co-infection. Maternal morbidity was almost three times greater (OR 2.8, 95% CI 1.7-4.6; I 2 = 60.3%) in pregnant women with TB than in the control group. The odds of antenatal admission were nine times greater (OR 9.6, 95% CI 2.3-40.6). The odds of maternal anaemia were four times greater in the TB group than in the control group (OR 3.85, 95% CI 2.21-6.71; I 2 = 29.8%). Caesarean section was performed twice as often in women with TB (OR 2.10, 95% CI 1.17-3.79; I 2 = 61%). The odds of miscarriage were nine times greater in women with TB (OR 9.0, 95% CI 4.93-16.67; Figure 3) .
A sensitivity analysis excluding studies of high risk of bias was compatible in direction and size of association observed in the majority of studies and outcomes, where the analysis was possible ( Figure S1 ).
Of the perinatal outcomes, perinatal death was four times more frequent in babies born to mothers with TB (OR 4.2, 95% CI 1.49-11.83; I 2 = 57.2%), preterm birth was 1.6 times greater (OR 1.7, 95% CI 1.2-2.4; I 2 = 66.5%), and low birthweight was 1.7 times greater (OR 1.7, 95% CI 1.2-2.4; I 2 = 83.1%). Low Apgar score at 1 minute was five times greater (OR 5.71, 95% CI 1.4-22.6) and acute fetal distress was 2.3 times greater (OR 2.34, 95% CI 1.2-4.5; I 2 = 0%) compared with babies born in the control group (Figure 4 ). There was a non-significant difference for the risks of small for gestational age (OR 1.7, 95% CI 0.76-4.2; I 2 = 83%), and congenital anomalies (OR 3.4, 95% CI 0.71-16.7; I 2 = 73%). A sensitivity analysis excluding studies of high risk of bias was compatible in direction and size of association observed in all studies and outcomes, where the analysis was possible ( Figure S2) .
Babies born to mothers with TB had a lower mean birthweight (weighted mean difference À278.25 g (95% CI À367.21 to À0.189.29; I 2 = 40.7%) and were born at an earlier gestation (weighted mean difference À0.84 weeks; 95% CI À1.22 to À0.47; I 2 = 35.6%) compared with those born to mothers without TB ( Figure S3 ).
Outcomes by site of disease
With regard to site of TB disease, four studies presented data exclusively on pulmonary disease [16] [17] [18] [19] and two studies on extra-pulmonary TB. 15, 20 There was a trend towards worse maternal outcomes with extra-pulmonary TB (Table S2) . Additionally, in one study 20 in women with extra-pulmonary TB, those who had lymph node disease had no adverse outcomes; however, TB at other extra-pulmonary sites did adversely affect pregnancy.
Outcomes by timing of diagnosis
Breakdown of outcomes by timing of diagnosis and treatment showed better outcomes when treatment was initiated in the first trimester in comparison with the second and third trimesters. In one study, none (0/9) of the pregnant women who were treated in the first trimester had a preterm birth, compared with 33% (4/12) who initiated treatment in the second and third trimesters. 21 For those who were treated in the first trimester, there were no cases (0/9) of perinatal death, compared with 23% (3/13) in those treated in the second and third trimesters. In mothers who were treated in the first trimester 29% (2/7) developed complications compared to 60% (6/10) in those who were treated in the second and third trimester. Another study 22 also found that no woman (0/23) who was treated in the first trimester had a baby with low birthweight, in comparison with 61% (33/54) in those treated in the second and third trimesters.
Discussion
Main findings
Our systematic review highlights that maternal and perinatal outcomes were consistently poorer in pregnant women with active TB than in women without. There were increased odds of maternal morbidity, anaemia, perinatal death, preterm birth, low birthweight and fetal distress in pregnant women with active TB. The outcomes were worse when anti-tuberculous treatment (ATT) was started late.
Strengths and limitations
To our knowledge, this is the first review that systematically evaluates the risk of active TB in pregnancy. The review was carried out in a stringent manner to reduce bias. Furthermore, this review provides the best available evidence summary on the effect of active TB infection on several maternal and fetal outcomes.
Although the studies included a significant number of patients with active TB, not all studies had data available for all maternal and perinatal outcomes. Furthermore, although most studies included information on site of disease and timing of diagnosis, this was not linked to maternal and perinatal outcomes, making subgroup analysis difficult. Between-study heterogeneity was moderate for a number of outcomes. In addition, some of the metaanalyses were based on a small number of studies. Both these facts should be taken into account when interpreting the results. Studies used different treatment regimens, which may represent an unexplored source of heterogeneity. There was a medium risk of bias in 43% of studies; however, after excluding these studies in a sensitivity analysis, there was still significantly poorer maternal and fetal outcomes in women with TB than in those without. Congenital TB is rare but causes significant morbidity to the infant; unfortunately, this was not reported in any of the included studies. 
Interpretation
Clinical diagnosis of active TB in pregnant women can be difficult and there is often a delay in diagnosis due to the non-specific symptoms related to the physiological response to pregnancy. 23 In low and middle income countries, where TB may represent the greatest burden, pregnancy may be one of the few opportunities to assess a woman's health. Pregnancy is therefore an ideal opportunity to screen for active TB disease; this is in line with the WHO recommendation of integrating TB screening and investigation into reproductive health services including antenatal and postnatal care in HIV-and TB-prevalent regions. 4 Different tests have been used in antenatal care, such as symptom check, routine sputum smear examination, 24, 25 and the Xpert â MTB/RIF assay. 26, 27 However, there are no guidelines for routine screening for active TB in pregnancy. The tuberculin skin test and the interferon gamma release assays have been used to screen for latent TB infection (LTBI) in pregnancy; however, only HIV-infected pregnant women are prioritised for LTBI screening according to WHO guidelines. 28 The effects of active TB on pregnancy may be influenced by many factors, including the extent of the disease, site of the disease, other comorbidities and the timing of diagnosis and initiation of treatment. Over 50% of maternal mortality occurring in mothers with TB in pregnancy is thought to be due to co-infection with HIV. 29 Unfortunately, there were not many women with documented HIV infection included in our review. This may be explained by the fact that few large studies were conducted before HIV testing was done routinely. It is well known that women with TB/HIV coinfection have poorer outcomes. 30 Although studies on HIV/ TB co-infection have been conducted in pregnancy, these were excluded in our review because they did not include a control group.
Future large prospective studies are needed to examine further the effect of active TB on maternal and fetal outcomes in pregnancy, especially in regions with a high burden of disease such as sub-Saharan Africa and the Indian subcontinent. Risk factors affecting maternal and perinatal outcomes such as HIV co-infection, site of disease (pulmonary or extra-pulmonary), timing, type and length of ATT need to be studied further. Routine TB screening in pregnancy may reduce delay in TB diagnosis and improve perinatal and maternal outcomes, which should be a topic of future studies.
Conclusion
Active TB disease in pregnancy is associated with adverse pregnancy outcomes. Early diagnosis of TB in the antenatal period is important to prevent significant maternal and perinatal morbidity and mortality.
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